Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Europe: Vaccination more often part of growing strategy

Did you ever think about vaccinating your crop against Pepino Mosaic Virus?

"We see that growers not only vaccinate to keep the crop healthy, but that vaccination is part of their production strategy," according to Annelies Justé from DCM. The company is known for their vaccine against Pepino mosaic virus PMV®-01, among other things. This year the company also hopes to receive final approval for their product in the Netherlands.

The Pepino mosaic virus is an important topic in the European greenhouse tomato industry. The virus has made an advance in the past decade. Fortunately, at the same time various means have been developed to prevent or restrict aggressive infection. One of these is DCM’s vaccine PMV®-01. The agent was first admitted on the Dutch market in 2012 and is now working on its seventh temporary admission, given the various exemptions for lit and unlit cultivation.

Now that the European dossier was approved by Belgium in December 2015, Annelies Justé expects that the final admission in the Netherlands won’t take much longer.

"Then growers can be sure to have it at their disposal at any time of the year in the future as well." The product is already legally available year round in several European countries like France, Belgium, the Czech Republic and the UK. "We have achieved this vaccine through basic research. With quality controls we can guarantee the stability and purity of PMV®-01 every year," says Justé.

Watch the video about application of the Pepino vaccine in Moroccan cultivation

One strain
Unlike with other vaccines, DCM is using only one strain of the virus. That was a conscious choice. "On one hand because several strains can exchange RNA, which may result in the rise of new strains," according to Justé. The DCM vaccine has been developed based on the Chilean strain. "The CH2 strain is the most common and dominant strain of the virus in Europe. In recent years, the Chilean chain has virtually supplanted the European strain." In order to guarantee that the vaccine has the desired result, vaccination samples are taken before and after.

According to DCM, vaccination with 1 strain also results in more energy for both the growth of the plant and tomato production. "This is especially important in unlit cultivation, as long as there is sufficient energy at the time of planting. After vaccination with PMV®-01 there is no plant standstill." Because DCM monitors both plant health as cultivation developments after vaccination. "We see that growers administer the vaccine at an appropriate time to ensure plant health, so they can then control generativity with a vital plant. As such, vaccination is not only a means, but part of the entire strategy."

For more information:
Annelies Justé
Valkenburgseweg 62-a
2223 KE Katwijk
Tel: 071 – 4018844
E: [email protected]